We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Affymetrix Names Kevin King President of Life Sciences Business

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Affymetrix Inc. has announced that it has appointed Kevin M. King to president of life sciences business and executive vice president, reporting to Stephen P.A. Fodor, Ph.D., chairman and CEO.

King previously served as president and CEO of Thomson Healthcare, the $500 million healthcare and pharmaceutical information services division of Thomson Corporation.

"We are very pleased to add Kevin King to the Affymetrix executive management team," said Fodor.

"He is an experienced leader and his proven track record of operational success in the life sciences industry provides Affymetrix with a solid foundation for continued commercial growth."

According to Affymetrix, King will be responsible for managing its life sciences business, which serves hundreds of academic, government, pharmaceutical and industrial customers around the world. He brings more than 25 years of industry experience to Affymetrix.

At Thomson Healthcare, King was responsible for developing and implementing the growth strategy. King has also held senior executive positions at General Electric Healthcare, including vice president and general manager, Global Clinical Systems.

In addition, King brings more than 14 years of experience at Hewlett-Packard, where his many accomplishments included the creation of a web-enabled systems strategy.

"Affymetrix microarray technology has quickly become the gold standard in life science research," said King.

"I look forward to being a part of such a quality organization that has tremendous opportunities to accelerate scientific research and improve patient care."